Table 2 Demographic characteristics and clinical profile of ALS and SBMA patients, and healthy control participants.

From: Central neurodegeneration in Kennedy’s disease accompanies peripheral motor dysfunction

 

SBMA (n = 12)

ALS (n = 8)

Control (n = 7)

P-value

Age (y.o)

63.1 (12.5)

65.4 (9.4)

67.3 (9.4)

0.68

Gender (M/F)

12 M

8 M

7 M

–

Handedness (L/R/B)

1L; 11R

1L; 7R

6R; 1B

0.57

Disease duration (years)

9 (4.8)

1.2 (1.2)

–

 < 0.01

ALSFRS-RTotal (/48)

38 (4.4)

38.8 (8)

–

0.82

Disease progression rate (48 – ALSFRS-R/duration)

0.09 (0.05)

0.35 (0.3)

–

0.04

TNSc (/24)

9.2 (3.8)

–

–

–

CAG repeat

43.8 (1.9)

–

–

–

  1. Mean and standard deviation.
  2. Disease duration for SBMA patients calculated from date of clinical diagnosis.
  3. *ALSFRS-R revised ALS functional rating scale, TNSc total neuropathy score clinical version.
Back to article page